SPOT-MAS™ Multi-Cancer Early Detection
SPOT-MAS is a blood-based multi-cancer early detection test designed to look for cancer-associated signals in circulating cell-free DNA. It may be considered as an additional screening tool for selected adults, but it is not a cancer diagnosis and it does not replace established screening programmes.
This page covers the specific test. For the wider question of whether multi-cancer blood screening is worth doing at all — including why positive predictive value matters more than specificity, and what the evidence has not yet shown — read the MCED guide first.
A screening signal is not a diagnosis
MCED tests analyse patterns in blood that may be associated with cancer. A positive result means further medical evaluation is required to determine whether cancer is actually present and, if so, where it may be located.
A negative result cannot rule out cancer. Some cancers may not release a detectable signal, and performance can vary by cancer type and stage. This is why symptoms, examination findings, family history and conventional screening remain important.
One point deserves emphasis because it is easy to misread. Test performance figures are usually generated in studies comparing people already known to have cancer against healthy volunteers. Applied to ordinary screening, where cancer is uncommon among those tested, the proportion of positive results that turn out to be genuine is considerably lower than the headline sensitivity and specificity suggest. That is arithmetic rather than a criticism of any particular test, and it applies to every MCED product.
Where SPOT-MAS may fit
Additional screening
It may be discussed with selected adults who want an additional blood-based screening option after reviewing age, risk factors and the limitations of current MCED evidence.
Alongside standard screening
It does not replace recommended breast, cervical, colorectal, lung or other established screening where those programmes are indicated.
Doctor interpretation
Results should be interpreted in clinical context rather than treated as a stand-alone answer. Follow-up depends on the reported signal, symptoms and individual risk.
| Your situation | Is SPOT-MAS the right step? |
|---|---|
| You have symptoms — a lump, bleeding, weight loss, persistent pain | No. You need diagnostic assessment. A negative screen here would be actively misleading. |
| You are overdue for mammography, cervical or colorectal screening | Do those first. They have demonstrated mortality benefit; MCED does not yet. |
| You are up to date on screening and want broader coverage | A reasonable discussion, with the limitations understood. |
| You have a strong family history suggesting an inherited syndrome | Genetic assessment and specialist surveillance come first. |
| You are already under cancer surveillance | Discuss with the team managing that, rather than adding a test independently. |
| You would decline investigation of a positive result | Then testing is not advisable, since the result would have nowhere to go. |
| You are hoping for reassurance | Worth thinking carefully. A negative cannot provide the reassurance people usually want from it. |
Understanding possible results
When no cancer signal is detected
This lowers concern only within the limits of the test. It does not exclude cancer and should not change appropriate symptom investigation or routine screening schedules.
When a cancer signal is detected
A positive screening signal requires confirmatory investigation. Depending on the reported findings, this may involve imaging, specialist review, endoscopy, targeted laboratory tests or tissue diagnosis.
When investigation finds nothing
This happens, and it is worth anticipating. You are then left with an unresolved positive signal and a decision about whether to repeat imaging later. Some people find that ambiguity harder to live with than a definite answer in either direction.
False positives and false negatives
No cancer screening test is perfect. A false positive can lead to additional scans, procedures, cost and anxiety even when cancer is ultimately not found. A false negative can create false reassurance if the result is interpreted too broadly.
For this reason, Aquila presents MCED as an adjunct to established care rather than as a replacement for conventional cancer screening or diagnostic evaluation.
The Aquila screening pathway
1. Pre-test consultation
Review personal and family history, current symptoms, previous screening and whether an MCED test is appropriate for your goals.
2. Blood collection
The required sample is collected and processed according to the test provider's current laboratory protocol.
3. Result review
Your result is reviewed in context, including what it does not exclude and whether conventional screening is still due.
4. Follow-up if needed
If a cancer-associated signal is reported, we discuss the next appropriate diagnostic pathway and specialist referral where indicated.
5. Routine screening continues
Age- and risk-appropriate standard screening should continue unless your treating clinician advises otherwise.
6. Symptoms remain important
New or persistent symptoms should be assessed medically even after a negative screening result.
The pre-test consultation is not a formality. The most useful conversation happens before the blood is taken, and it is about what you would do with each possible result — because that is what determines whether the test helps you or simply generates uncertainty you did not have before.
Who should discuss suitability first?
- Adults with a strong family history of cancer.
- People with previous abnormal screening results who need clarification on the correct next step.
- Patients with active symptoms, who may need diagnostic testing rather than screening.
- People already under specialist cancer surveillance.
- Anyone considering delaying standard screening because of an MCED result.
- Anyone who would find an unresolved or ambiguous result difficult to manage.
How this differs from the main MCED page
This page focuses specifically on the SPOT-MAS branded test available through Aquila. For a broader explanation of multi-cancer early detection technology, evidence limits and how MCED fits with conventional screening, see our Multi-Cancer Early Detection guide.
You can also review our broader health screening services.
Frequently asked questions
Does SPOT-MAS diagnose cancer?
No. It is a screening test. A positive signal needs confirmatory medical investigation before a cancer diagnosis can be made.
Can a negative SPOT-MAS result rule out cancer?
No. A negative result does not exclude cancer and should not override symptoms, examination findings or recommended screening.
Can I use SPOT-MAS instead of mammography, colon screening or cervical screening?
No. MCED testing should not replace established screening programmes when you are eligible for them.
What happens after a positive result?
The next step is confirmatory evaluation tailored to the reported signal and your clinical context. This may require imaging, specialist assessment or other diagnostic tests.
Who should not rely on screening alone?
Anyone with concerning symptoms needs diagnostic medical assessment. Screening is intended for people without symptoms and cannot substitute for evaluation of a suspected illness.
Why might a positive result still be wrong?
Because cancer is uncommon among people being screened. Even a test with high specificity produces a substantial number of false alarms when the underlying rate is low — arithmetic that applies to every MCED product.
Are the published accuracy figures applicable to me?
Only partly. Performance is usually established comparing known cancer patients against healthy volunteers, and real-world screening performance is generally less favourable than those figures imply.
What if investigations find nothing after a positive signal?
That does happen, leaving an unresolved result and a decision about repeat imaging later. Some people find that ambiguity harder than a definite answer either way.
How do I compare SPOT-MAS with other MCED tests?
Cautiously. Different products report different panels and accuracy figures generated under different conditions, and a larger claimed panel is not automatically better if it brings more false alarms.
What does it cost overall?
The test is self-funded and any follow-up investigations are usually additional and may not be covered, so the potential total matters more than the blood test price.
Will insurance cover it?
Screening tests of this kind are frequently not covered. Check with your insurer, including whether investigations prompted by a screening result would be covered.
How often should it be repeated?
There is no established interval, partly because the evidence needed to define one does not exist. Any repeat should be a considered decision rather than an automatic annual booking.
Is it the same as a genetic cancer risk test?
No. Genetic testing assesses inherited predisposition; MCED looks for signals from cancer that may already be present. They answer different questions.
I just want reassurance — is this the right test?
Probably not, and that is worth thinking about honestly. A negative result cannot deliver the certainty most people are seeking, and a false positive can leave you considerably more anxious than before.
Should I have this before my colonoscopy?
No. Colorectal screening has demonstrated mortality benefit and should not be deferred in favour of a blood test that has not yet shown the same.
Does a detected signal tell me where the cancer is?
Some reports estimate a likely tissue of origin, which helps direct follow-up. It remains a prediction rather than proof of the site.
Can it detect early-stage cancer?
Sometimes, though detection is generally less sensitive at earlier stages when less tumour DNA is circulating — which is the stage where detection would be most valuable.
What is the single most important thing to understand?
That a negative does not mean cancer-free and a positive does not mean cancer. It shifts probability rather than delivering a verdict.
Is this test claimable under MediSave in Singapore?
Generally not. Check directly with your insurer or provider for current arrangements.
Where is Aquila Medical Center?
Aquila Medical Center is at 160 Robinson Road, #05-01 SBF Centre Medical Suites, Singapore 068914, in the CBD, a short walk from Tanjong Pagar, Shenton Way and Telok Ayer MRT stations.
Selected references
- Positive and Negative Predictive Value. StatPearls, NCBI Bookshelf.
- US National Cancer Institute. Multi-cancer detection tests.
- US National Cancer Institute. Overdiagnosis in cancer screening.
- Singapore HealthHub. Screen for Life national screening programme.
This page is educational and does not replace an individual medical consultation. SPOT-MAS is a screening test, not a diagnostic test. A negative result does not exclude cancer and a positive result requires confirmatory investigation. Multi-cancer early detection has not yet been shown in completed randomised trials to reduce cancer mortality, and established screening programmes should continue. Content reviewed by the medical team at Aquila Medical Center, Singapore. Last reviewed: 26 August 2026.
Discuss whether SPOT-MAS is appropriate for you
A pre-test consultation helps place the result in context and ensures conventional screening or diagnostic care is not delayed.
Where the more valuable step is completing screening you are already due, or investigating a symptom properly, we will tell you that instead.
Information on this page is for general education and does not replace individual medical advice.